Rapid Micro Biosystems (RPID) Margin Pressure Persists As Q4 Loss Deepens Despite Revenue Gain

Rapid Micro Biosystems (RPID) just posted its FY 2025 results with Q4 revenue of US$11.3 million and a basic EPS loss of US$0.28, alongside a Q4 net loss of US$12.5 million. The company has seen quarterly revenue move from US$8.2 million in Q4 FY 2024 to US$11.3 million in Q4 FY 2025. Over the same period, basic EPS shifted from a loss of US$0.22 to a loss of US$0.28, and trailing 12 month EPS for Q3 FY 2025 sits at a loss of US$1.00 on net losses of US$44.3 million. For investors, the story here is about how these revenue levels compare with ongoing losses and what that may indicate about the path for margins.

With the latest numbers on the table, the next step is to see how they compare with the widely discussed bull and bear narratives around Rapid Micro Biosystems and to consider which parts of the story those figures appear to support or challenge.

See what the community is saying about Rapid Micro Biosystems

Q4 loss of US$12.5 million keeps margins in the red

• Q4 FY 2025 net loss was US$12.5 million on US$11.3 million of revenue, so expenses still sit above the top line and the basic EPS loss of US$0.28 reflects that gap.
• Analysts' consensus view highlights that recurring consumables and service revenue can help margins over time, yet with trailing 12 month losses of US$44.3 million, investors still have to weigh:
  • Whether the current revenue base of about US$30.5 million over the last twelve months is enough to support the multiyear push toward breakeven that analysts are assuming.
  • How long the company can keep narrowing losses, given Q4 and trailing figures both sit firmly in loss making territory despite the improving trend cited at about 8.4% loss reduction per year over five years.

Revenue trend vs 8.4% loss improvement

• On a trailing 12 month basis, revenue has moved from US$24.7 million in Q2 FY 2024 to US$30.5 million by Q3 FY 2025, while losses over the same trailing periods went from US$50.5 million to US$44.3 million, consistent with the 8.4% annual reduction in losses mentioned in the analysis.
• Analysts' consensus narrative leans on rising demand for automated microbiology quality control and recurring consumables, and these trailing numbers give mixed signals:
  • On one hand, higher trailing revenue alongside narrower trailing losses supports the idea that a larger installed base and recurring revenue can help chip away at losses.
  • On the other hand, Q4 FY 2025 still shows a double digit million net loss, so even with a five year trend of loss reduction, the company remains far from the US$6.9 million earnings level analysts reference for 2028 in their scenario work.

P/S at 4.1x with shares at US$2.83

• With the share price at US$2.83 and a trailing P/S of 4.1x versus peers at 2.1x and the US Life Sciences industry at 2.7x, the stock trades on a higher sales multiple while the trailing 12 month EPS is a loss of about US$1.00.
• Analysts' consensus view calls out both the potential for revenue to reach US$48.8 million and earnings of US$6.9 million by around 2028 and the risks from ongoing losses, and today’s multiples put numbers behind that tension:
  • If the company were to reach the US$8.00 analyst target from the current US$2.83, that would imply a very large price move that depends on the revenue and margin path the analysts outline.
  • At the same time, the elevated P/S and recent share price volatility, plus insider selling in the last three months, are concrete factors investors can compare against those longer term revenue and earnings assumptions before deciding how comfortable they are with this valuation gap.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Rapid Micro Biosystems on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of opportunity and risk feels finely balanced, take a moment now to review the full picture and weigh it for yourself with 1 key reward and 3 important warning signs.

Explore Alternatives

Rapid Micro Biosystems is still reporting sizeable losses alongside relatively modest revenue and a higher P/S multiple, which makes the current risk reward trade off quite tight.

If that mix of ongoing losses and valuation questions feels uncomfortable, you can quickly compare it with 69 resilient stocks with low risk scores and see companies where our model flags more resilient profiles right now.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com